METHOD OF ASSESSING RISK OF HAVING INFLAMMATORY STATUS IN LONG TERM AFTER COVID-19 PNEUMONIA Russian patent published in 2024 - IPC G01N33/49 G01N33/72 G01N33/92 A61B5/107 A61B5/205 A61B3/00 

FIELD: medicine; therapy.

SUBSTANCE: invention can be used to assess the risk of having an inflammatory status in the long term after COVID-19 pneumonia. Three months after suffering from COVID-19 pneumonia, the degree of obesity, the level of blood leukocytes, the level of total blood cholesterol, the presence of microhemorrhages of the vessels of the epibulbar conjunctiva (EBK), the presence of the sludge phenomenon of the vessels of the EBK and the level of hemoglobin in the blood are determined. The percentage probability of having elevated C-reactive protein (CRP) 12 months after COVID-19 pneumonia is calculated using the formula %, where is Euler number, and is calculated by the formula , where – the numerical value of the degree of obesity, determined by BMI; is the level of blood leukocytes, 10⁹/l; is the total cholesterol level, ; — 1 in the presence of microhemorrhages of the vessels of the endothelium and 0 in their absence; — 1 in the presence of the sludge phenomenon of the EBC vessels and 0 in their absence; is blood hemoglobin level, g/l. With a calculated probability of 35% or higher, the risk of having an inflammatory status 12 months after hospitalization is assessed as high. For values less than 35%, the risk is assessed as low.

EFFECT: method provides the ability to assess the risk of having an inflammatory status in patients in the long-term period after COVID-19 pneumonia by calculating the probability of having elevated CRP.

1 cl, 1 tbl, 2 ex